Alimera Sciences
Alimera Sciences is a biopharmaceutical company that develops and commercializes FDA-approved sustained-release intravitreal implants (YUTIQ and ILUVIEN) for chronic non-infectious uveitis and diabetic macular edema, serving ophthalmologists and retina specialists across the US and Europe. Acquired by ANI Pharmaceuticals in September 2024.
- Company typePrivate
- Founded2003
- HeadquartersAlpharetta, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Alimera Sciences does
Alimera Sciences is a biopharmaceutical company that develops and commercializes sustained-release intravitreal implants for retinal disease. The company's product portfolio consists of two FDA-approved corticosteroid implants: YUTIQ (fluocinolone acetonide intravitreal implant, 0.18 mg), approved for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, and ILUVIEN (fluocinolone acetonide intravitreal implant, 0.19 mg), approved for diabetic macular edema. Both products share the same proprietary platform architecture, delivering sustained release of fluocinolone acetonide over approximately 36 months from a single intravitreal injection, eliminating the need for repeated intraocular injections and addressing the compliance and treatment-burden challenges associated with chronic retinal inflammation.
Alimera serves a narrow specialist customer base — ophthalmologists and retina specialists who treat chronic inflammatory and diabetic retinal conditions — and reaches patients through specialty pharmacy distribution and direct relationships with ophthalmology clinics across the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan. The company monetizes primarily through prescription product sales to healthcare providers and payers at undisclosed specialty pharmaceutical pricing, supplemented by royalty streams associated with its intravitreal implant franchise. YUTIQ generated USD 28.3 million in 2022, a 67% increase over 2021, indicating accelerating commercial uptake heading into the acquisition.
In September 2024, Alimera Sciences was acquired by ANI Pharmaceuticals (NASDAQ: ANIP), becoming a wholly-owned subsidiary integrated into ANI's retina-focused rare disease business. Post-acquisition, ANI further consolidated the franchise's economics by acquiring a 3.125% perpetual royalty obligation on YUTIQ and ILUVIEN net revenues from SWK Funding LLC for USD 17.25 million in March 2025. The company had previously been publicly listed on NASDAQ under the ticker ALIM prior to delisting following the ANI transaction.
Alimera Sciences firmographics
Firmographics- Name
- Alimera Sciences
- Legal name
- Alimera Sciences
- Website
- https://alimerasciences.com
- Company type
- Private
- Founded year
- 2003
- Operating status
- Acquired
- Headcount range
- 51–100 employees
- Short description
- Alimera Sciences is a biopharmaceutical company that develops and commercializes FDA-approved sustained-release intravitreal implants (YUTIQ and ILUVIEN) for chronic non-infectious uveitis and diabetic macular edema, serving ophthalmologists and retina specialists across the US and Europe. Acquired by ANI Pharmaceuticals in September 2024.
- Ownership category
- akta.pro rank
Alimera Sciences industry classification
Industry- Product category
- Ophthalmic Pharmaceuticals
- NAICS
- Surgical Appliance and Supplies Manufacturing (339113), Ophthalmic Goods Manufacturing (339115)
- SIC
- Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Ophthalmology Pharmaceuticals (HLAIAAAL)
- akta.pro secondary industry
- Ophthalmology Specialty Pharmaceuticals (HLAIACAK)
Keywords
Where Alimera Sciences is headquartered
LocationHeadquarters
- HQ city
- Alpharetta
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Alimera Sciences business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain
Revenue model
- Product Sales - YUTIQ: Sales of FDA-approved YUTIQ intravitreal implant for chronic non-infectious uveitis. YUTIQ generated USD 28.3 million in 2022 (67% increase from 2021).
- Product Sales - ILUVIEN: Sales of ILUVIEN intravitreal implant for diabetic macular edema. ILUVIEN generates ongoing royalties as part of ANI Pharmaceuticals' retina-focused business following the September 2024 acquisition.
- Royalty Revenue: In March 2025, ANI Pharmaceuticals acquired a 3.125% perpetual royalty obligation on YUTIQ and ILUVIEN net revenues from SWK Funding LLC for USD 17.25 million, indicating ongoing royalty streams from these products.
Distribution channels2 records
Marketing channels3 records
Alimera Sciences product offering
Product offeringCore offering
Alimera Sciences develops, manufactures, and commercializes FDA-approved intravitreal implants for retinal disease. Its two commercial products — YUTIQ (fluocinolone acetonide intravitreal implant 0.18 mg) for chronic non-infectious uveitis affecting the posterior segment, and ILUVIEN (fluocinolone acetonide intravitreal implant 0.19 mg) for diabetic macular edema — deliver sustained corticosteroid release for approximately 36 months, reducing the need for repeated intravitreal injections. Following its September 2024 acquisition by ANI Pharmaceuticals, the products are sold to ophthalmology and retina specialists through specialty pharmacy and direct specialty distribution channels.
Product overview
Alimera Sciences was a pharmaceutical company specializing in ophthalmic therapeutics, focused on the development and commercialization of prescription ophthalmic pharmaceuticals. Following its acquisition by ANI Pharmaceuticals in September 2024, Alimera's portfolio consists primarily of two sustained-release intravitreal implants: YUTIQ (for chronic non-infectious uveitis) and ILUVIEN (for diabetic macular edema). Both products deliver fluocinolone acetonide via proprietary intravitreal implant technology providing sustained drug release over extended periods. The portfolio addresses retinal disease conditions and is commercialized primarily in the United States with international market presence.
Differentiator
Problem solved
Functional benefit
Brands
- YUTIQ: FDA-approved intravitreal implant for chronic non-infectious uveitis
- ILUVIEN
Products and services
- YUTIQ YUTIQ is an FDA-approved intravitreal implant indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The implant provides sustained release of fluocinolone acetonide over approximately 36 months, reducing the need for repeated intravitreal injections and addressing long-term treatment burden for patients with chronic posterior uveitis.
- ILUVIEN ILUVIEN is an intravitreal corticosteroid implant indicated for the treatment of diabetic macular edema (DME). It provides sustained delivery of fluocinolone acetonide over an extended period, offering an alternative to frequent intravitreal injections for patients with diabetic eye disease requiring long-acting anti-inflammatory therapy.
Companies that use Alimera Sciences
Customer profileNamed customers2 records
Segments2 records
Ideal customer profiles1 record
Alimera Sciences technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Alimera Sciences partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- ANI PharmaceuticalscoreANI Pharmaceuticals acquired Alimera Sciences in September 2024, strengthening its retina-focused business portfolio. The acquisition included Alimera's products YUTIQ and ILUVIEN, both FDA-approved intravitreal implants for ophthalmic conditions.
Scale indicators3 records
Recent moves5 records
Expansion highlights4 records
Alimera Sciences competitors and assessment
Company assessmentDirect peers
- EyePoint Pharmaceuticals: EyePoint Pharmaceuticals develops sustained-release ocular drug delivery implants including DURYSTA (bimatoprost intracameral implant) and is a direct competitor in long-duration ophthalmic implants. Both companies target sustained drug delivery in the eye with biodegradable implant technology addressing chronic retinal and glaucoma conditions.
Broad incumbents
- Regeneron Pharmaceuticals: Regeneron commercializes Eylea (aflibercept), the dominant anti-VEGF therapy for diabetic macular edema and other retinal diseases. Eylea is the leading first-line DME treatment that competes directly against ILUVIEN for the same patient population, positioning Regeneron as a broad incumbent in the retinal therapeutics market.
- Roche / Genentech: Roche/Genentech markets Lucentis (ranibizumab) and Susvimo, both used in diabetic macular edema and other retinal conditions. As a broad incumbent in ophthalmology biologics, Roche represents the established anti-VEGF paradigm against which ILUVIEN's steroid implant positioning must compete.
- Novartis: Novartis commercializes Beovu (brolucizumab) for DME and related retinal conditions and has a broad ophthalmology portfolio. Novartis competes with Alimera's franchise for retinal specialists' prescribing share in DME and represents a broad incumbent with deep commercial reach.
- Bausch + Lomb: Bausch + Lomb is a diversified ophthalmology company with products spanning retinal disease, glaucoma, dry eye, and surgical devices. Its retinal franchise (including the recently divested Bausch + Lomb Stellaris Elite and anti-VEGF partnerships) competes broadly with Alimera's specialty pharma focus.
- IVERIC bio (Astellas): IVERIC bio (now part of Astellas following 2023 acquisition) developed Izervay for geographic atrophy and other retinal therapeutics. As a retinal-focused player now integrated into a global pharma, it represents a comparable trajectory of ophthalmic specialty biotech being absorbed by a larger strategic buyer.
Emerging players
- Clearside Biomedical: Clearside Biomedical develops suprachoroidal drug delivery technology for retinal diseases, including XIPERE (triamcinolone acetonide suprachoroidal injectable) for uveitic macular edema. Clearside is an emerging competitor targeting the same uveitis patient population as YUTIQ via a different delivery route.
- Adverum Biotechnologies: Adverum is developing ADVM-022 (ixoberogene soroparvovec), a gene therapy targeting diabetic macular edema and wet AMD via single intravitreal injection. As an emerging player with a long-acting treatment paradigm for DME, Adverum represents a future competitive threat to ILUVIEN.
- Kodiak Sciences: Kodiak Sciences develops KSI-301 (tarcocimab tedromer), an antibody biopolymer conjugate for retinal vascular diseases including DME. Kodiak is an emerging player pursuing longer-dosing-interval anti-VEGF therapy that could pressure conventional treatment paradigms in DME.
- Outlook Therapeutics: Outlook Therapeutics is developing ONS-5010 / LYTENAVA, an ophthalmic formulation of bevacizumab for wet AMD and other retinal conditions. As an emerging biosimilar-style player targeting retinal disease, Outlook represents potential future competition in the broader DME treatment landscape.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights5 records
Customer concentration
Alimera Sciences social profiles
Digital presenceAlimera Sciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
Alimera Sciences leadership team
Management profileNumber of profiles
Profiles11 records
Alimera Sciences funding detail
Funding detailFunding overview
Funding rounds11 records
Investors12 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Alimera Sciences M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Alimera Sciences
What does Alimera Sciences do?
Alimera Sciences develops, manufactures, and commercializes FDA-approved intravitreal implants for retinal disease. Its two commercial products — YUTIQ (fluocinolone acetonide intravitreal implant 0.18 mg) for chronic non-infectious uveitis affecting the posterior segment, and ILUVIEN (fluocinolone acetonide intravitreal implant 0.19 mg) for diabetic macular edema — deliver sustained corticosteroid release for approximately 36 months, reducing the need for repeated intravitreal injections. Following its September 2024 acquisition by ANI Pharmaceuticals, the products are sold to ophthalmology and retina specialists through specialty pharmacy and direct specialty distribution channels.
Is Alimera Sciences a public or private company?
Alimera Sciences is a private company. It is classified as corporate owned and is currently acquired.
When was Alimera Sciences founded?
Alimera Sciences was founded in 2003. It employs 51 to 100 people.
Where is Alimera Sciences based?
Alimera Sciences is headquartered in Alpharetta, United States, in the North America region.
How does Alimera Sciences make money?
Three revenue lines are on record. Product Sales - YUTIQ is the primary driver. The others are product Sales - ILUVIEN and royalty Revenue.
Who are Alimera Sciences's main competitors?
EyePoint Pharmaceuticals is listed as a direct peer. Broad incumbents are Regeneron Pharmaceuticals, Roche / Genentech, Novartis, Bausch + Lomb and IVERIC bio (Astellas). Emerging players are Clearside Biomedical, Adverum Biotechnologies, Kodiak Sciences and Outlook Therapeutics.
Does Alimera Sciences have an API?
No public API is recorded for Alimera Sciences.
What industry is Alimera Sciences in?
Alimera Sciences's product category is Ophthalmic Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAL, Ophthalmology Pharmaceuticals, with a secondary code of HLAIACAK, Ophthalmology Specialty Pharmaceuticals. Its NAICS code is 339113 and its SIC code is 2834.